Further impressive data for Takeda's dengue vaccine

24 May 2021

Takeda’s (TYO: 4502) dengue vaccine candidate (TAK-003) has demonstrated continued protection against illness and hospitalization, regardless of a person’s previous dengue exposure, with no important safety risks identified through three years after vaccination in the ongoing pivotal Phase III Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial.

TIDES enrolled more than 20,000 healthy children and adolescents aged four to 16 years in dengue-endemic countries in Latin America and Asia. Safety and efficacy results from the 36-month follow-up exploratory analysis were presented on Saturday.

"Our dengue vaccine candidate continued to provide protection against dengue throughout three years"LakKumar Fernando, center for clinical management of Dengue and Dengue Haemorrhagic Fever, Negombo General Hospital, Sri Lanka and a primary investigator of the TIDES trial, said: “Dengue epidemics occur suddenly, and hospitals can become overwhelmed with severe disease cases and people seeking testing.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK